Objective: To investigate the molecular interaction patterns between CD46/TREM1 and LC3B/ATG5 in the development of oral squamous cell carcinoma (OSCC), providing novel targets for elucidating the mechanism of inflammatory-to-cancer progression and for the early diagnosis and treatment of OSCC. Methods: An oral inflammation-to-cancer progression animal model was established using 4-Nitroquinoline-N-oxide (4-NQO) drinking water and/or lipopolysaccharide (LPS). Clinical oral leukoplakia (OLK), OSCC, and adjacent non-cancerous tissues were collected. Immunohistochemistry assessed CD46, TREM1, LC3B, ATG5 protein expression and PI3K-AKT/TNF pathway alterations in animal and clinical tissues. Enzyme-Linked Immunosorbent Assay (ELISA) measured inflammatory cytokine levels in serum and saliva. High-throughput sequencing analyzed key pathways. Results: Immunohistochemistry revealed elevated CD46/TREM1 expression and reduced LC3B/ATG5 expression in OSCC tissues ( P < 0.05). Serum levels of IL-6, IL-8, and GROα/CXCL1 progressively increased with advancing inflammation-to-cancer progression in rats, whereas salivary expression peaks occurred during the inflammatory phase. In human saliva and serum, TNF-α, IL-8, and IL-6 exhibited an increasing trend among healthy individuals, oral leukoplakia patients, and OSCC patients ( P < 0.05). Transcriptome analysis revealed a significant increase in differentially expressed genes during the transformation from OLK to OSCC, predominantly downregulated genes. Among these, Col4a6 and Csf2 genes participated in inflammation-to-cancer progression by regulating the PI3K-Akt and TNF pathways. Conclusion: CD46 and TREM1 are highly expressed in OSCC and serve as key initiating factors in the progression from OLK to OSCC. Bioinformatics analysis identified critical candidate genes ( Col4a6 , Csf2 ) and pathways (PI3K-Akt, TNF) in inflammation-to-cancer conversion. Activation of the PI3K-AKT-mTOR pathway is associated with inhibited autophagy and malignant progression of OSCC. Additionally, inflammation-to-cancer transition is a core mechanism in the development of OSCC, with the tumor inflammatory microenvironment acting as a “promoter” in the progression from OLK to OSCC. This study provides novel insights into the molecular mechanisms and targeted therapies for OSCC, holding significant theoretical and clinical application value.
Objective: To study SP22 the closed short peptide of CD59 specific site on Jurkat cell signal transduction molecules (LAT, STAT3) genes, proliferation genes (Nf-κb3, Bcl-2) and apoptosis genes (caspase-3) effect, research CD59 specific site closed by short peptide concrete mechanism of Jurkat cells. Methods: Jurkat cells were divided into blank control group and SP22 peptide closed group, Training after 48h respectively with the method of CCK 8 to detect each cell proliferation rate; Flow cytometry -- check each group cell apoptosis; Real time quantitative PCR --from gene level determination of two kinds of cells before and after the experiment the expression of stat3 and joint protein Lat, detection of cell proliferation and apoptosis protein before and after test the Nf-κb3, Bcl-2, the expression of Caspas-3; Enzyme-linked immunosorbent assay (ELISA) to detect the related cytokines. Results: add SP22 peptide group cell proliferation inhibition rate is greater than the blank control group (P < 0.01);Add SP22 group compared with blank control group Lat, Stat3, Nf-κb3, Bcl-2 gene expression decline, Caspas-3 gene expression rise; Add SP22 40 mg group cell death ratio increased, compared with the blank control group difference has statistically significant (P < 0.01). In short peptide SP22 group, cells secrete and promote tumor to growth of interleukin 2 (IL-2) and TGF-βhad been inhibited. Conclusion: CD59 specific site closed short peptide can inhibit Jurkat cell proliferation, reduce the expression of Lat, Stat3, Nf-κb and Bcl-2, activating caspase-3, promote the apoptosis of Jurkat cells.